The largest community of pharma leaders

Geron Announces Opening of IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis

FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the opening for patient screening and enrollment of the IMpactMF Phase 3 clinical trial of imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF). “As Geron’s second registration-enabling Phase 3 trial in hematologic myeloid malignancies, the IMpactMF trial represents a milestone for our Company,” said Aleksandra Rizo, M.D., Ph.D.,

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles